MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $140K rose 180.0% year over year, ahead of the +39.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 77.2% from the prior quarter. Over 3 fiscal years it compounded at +64.2% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +180.0% holds above the trailing-twelve-month pace of +39.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 248K USD
- Year-over-year change
- +1.6%
- 3-year CAGR
- +64.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 248K | +1.6% |
| FY2024 | 2024-12-31 | 244K | +55.4% |
| FY2023 | 2023-12-31 | 157K | +180.4% |
| FY2022 | 2022-12-31 | 56K | — |
Depreciation & Amortization vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.4% is the highest of 8, against a peer median of -27.5%.
- Over three fiscal years its annual growth of +64.2% compares with a peer median of -1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €18.33M EUR | +5.7% | -1.8% | 1.5% | |
| LTM Mar 2026 | $12.47M USD | +3.0% | -1.4% | 4.0% | |
| LTM Sep 2026 | $1.02M USD | -29.4% | -7.2% | 0.4% | |
| LTM Mar 2026 | $960K USD | -46.5% | +26.8% | — | |
| LTM Jun 2026 | $450K USD | +7.1% | +14.0% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $343K USD | +39.4% | +64.2% | — |
KLRAKailera Therapeutics, Inc. | FY2025 | $310K USD | — | — | — |
| LTM Mar 2026 | $121K USD | -27.5% | +27.8% | — | |
| LTM Mar 2026 | $106K USD | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding MBX) | — | -27.5% | -1.4% | 2.7% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 306K | 2.04M | 5.22M | 8.68M |
| Change in Working Capital | 1.29M | (735K) | 4.6M | 1.58M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 671K | 412K | 3.93M | (2.46M) |
| Other Working Capital | 619K | (1.15M) | 670K | 4.03M |
| Other Non-Cash Items | 1.36M | (880K) | (2.82M) | (3.48M) |
| Operating Cash Flow | (23.12M) | (31.98M) | (54.68M) | (79.95M) |
| Capital Expenditures | (441K) | (129K) | (874K) | (1.93M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.22M) | (63.8M) | (239.47M) | (358.15M) |
| Sales of Investments | 9.25M | 33M | 79.75M | 267.87M |
| Other Investing Activities | 0 | 0 | 0 | 8.5M |
| Investing Cash Flow | (11.41M) | (30.93M) | (160.6M) | (83.71M) |
| Debt Repayment | 10M | 0 | 0 | 0 |
| Common Stock Issued | 30K | 739K | 174.54M | 189.59M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (428K) | (30K) | (3.94M) | 0 |
| Financing Cash Flow | 46.06M | 69.22M | 234.1M | 189.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.53M | 6.31M | 18.83M | 25.94M |
| Free Cash Flow | (23.56M) | (32.11M) | (55.56M) | (81.88M) |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.